NEFL and amyotrophic lateral sclerosis: Currently, there are no specific biomarkers for ALS; ongoing research focuses on broad neurodegeneration markers (such as p75ECD, phosphorylated neurofilament heavy chain, and neurofilament light) or inflammatory cytokines that require complex combinations to distinguish ALS patient samples6,7.